News
KURA
--
0.00%
--
Global Mitogen Activated Protein Kinase 1 Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Mitogen Activated Protein Kinase 1 market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 1d ago
GURE, ASO, PRVB and WDFC among after-hours movers
Gainers: [[GURE]] +27.1%. [[ASO]] +8.4%. [[MRSN]] +6.2%. [[CLOV]] +5.8%. [[OTIC]] +3.2%.Losers: [[PRVB]] -37.9%. [[KURA]] -9.7%. [[WDFC]] -7.3%. [[MRKR]] -6.4%. [[PETQ]] -6.1%.
Seekingalpha · 04/08 21:40
Mitogen Activated Protein Kinase 1 Market Statistics, CAGR, Outlook, and Covid-19 Impact 2021-2027
Apr 05, 2021 (Market Insight Reports) -- The latest report as Mitogen Activated Protein Kinase 1 Market acknowledges Size, Application Segment, Type,...
Market Insight Reports · 04/05 11:05
Is KURA Stock A Buy or Sell?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite ...
Insider Monkey · 03/29 20:13
Kura Oncology Announces The Publication Of Its Tipifarnib Phase 2 Data In Journal Of Clinical Oncology
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –   – Statistically significant improvement in median
Benzinga · 03/22 20:12
Potbelly and Shake Shack lead restaurant sector higher
Potbelly ([[PBPB]] +15.5%) and Shake Shack ([[SHAK]] +6.0%) are two of the big gainers in the restaurant sector on more anecdotal reports of increased dine-in traffic and further loosening of
Seekingalpha · 03/15 17:25
Global Mitogen Activated Protein Kinase 1 Market Size, Share, Value, and Competitive Landscape 2024
Heraldkeepers · 03/13 04:29
Mitogen Activated Protein Kinase 9 Market Global Growth, New Updates 2021 Overview, Industry Expansion, Opportunities, Market by Type, Size, Share, by Manufacturers, Regional Analysis & Forecast by 2025
Mar 01, 2021 (The Expresswire) -- Global “Mitogen Activated Protein Kinase 9 Market” report presents an in-depth analysis of market development. The report...
The Express Wire · 03/01 08:25
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Lantheus (LNTH)
SmarterAnalyst · 02/26 13:15
8-K: Kura Oncology, Inc.
(EDGAR Online via COMTEX) -- false 0001422143 0001422143 2021-02-24 2021-02-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 00:33
DJ Kura Oncology, Inc. CEO Troy Wilson on Q4 2020 Results -- Earnings Call Transcript >KURA
Dow Jones · 02/24 18:52
FSR, SUNW, OSTK and DKL among midday movers
Gainers: Sypris Solutions (SYPR) +83%.9F (JFU) +39%.Owens & Minor (OMI) +38%.Sunworks (SUNW) +34%.R. R. Donnelley & Sons (RRD) +30%.Fisker (FSR) +28%.PubMatic (PUBM) +27%.dMY Technology (DMYI) +26%.Timber Pharmaceuticals (TMBR) +25%.Cancer Genetics (CGIX) ...
Seekingalpha · 02/24 17:49
DJ Kura Oncology Price Target Cut to $43.00/Share From $45.00 by HC Wainwright & Co.
Dow Jones · 02/24 16:12
DJ Kura Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/24 16:12
Kura Oncology (KURA) Gets a Buy Rating from H.C. Wainwright
SmarterAnalyst · 02/24 15:35
Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer
Benzinga · 02/24 14:12
10-K: KURA ONCOLOGY, INC.
Edgar Online - (EDG = 10Q, 10K) · 02/24 12:33
DJ Kura Oncology Gets FDA Breakthrough Therapy Designation for Tipifarnib
Dow Jones · 02/24 12:32
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23)
Benzinga · 02/24 12:30
Kura climbs on FDA breakthrough therapy status for tipifarnib in head and neck carcinoma
Kura Oncology (KURA) has added ~14.1% in the premarket after announcing that it has received the breakthrough therapy designation from the FDA for tipifarnib in the treatment of recurrent or metastatic HRAS mutant head
Seekingalpha · 02/24 12:27
Webull provides a variety of real-time KURA stock news. You can receive the latest news about Kura Oncology through multiple platforms. This information may help you make smarter investment decisions.
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.